---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-055698"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:45:39.130843+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics Q3 2021: cash $290.5M; BDC-1001 interim data at ESMO I-O in Dec

## Summary
- Cash, cash equivalents and marketable securities $290.5M at Sep 30, 2021; plus $5M upfront from Innovent in Oct.
- Operating loss $23.5M in Q3 2021 vs $12.4M in Q3 2020; R&D expenses rose to $19.3M.
- BDC-1001 Phase 1/2 monotherapy interim data (>50 patients) to be presented at ESMO I-O Congress in Dec 2021.
- Combination dose escalation with Opdivo expected to start Q4 2021; collaboration with Innovent for up to 3 ISACs.
- Cash expected to fund operations through end of 2023.

## SEC filing metadata
- accession: 0001564590-21-055698
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000156459021055698/0001564590-21-055698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000156459021055698/bolt-8k_20211109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-055698
- JSON: https://secwatch.observer/filing/0001564590-21-055698.json
- Plain text: https://secwatch.observer/filing/0001564590-21-055698.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.